Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.41 USD | -8.83% | -14.13% | +50.84% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.84% | 1.43B | |
+10.45% | 115B | |
+11.83% | 106B | |
-5.93% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.51% | 17.56B | |
-40.50% | 17.32B | |
+6.39% | 14.03B | |
+30.90% | 12.13B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. - Special Call